VRTX is pressing against trendline resistance after clean higher lows. A breakout above $469.80 could fuel a move toward $471.50.
🎯 Plan:
→ Entry: $468.41
→ SL: Below $466
→ Target: $471.50
⚠️ Wait for confirmation above structure.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
12.00 EUR
−517.38 M EUR
10.61 B EUR
255.58 M
About Vertex Pharmaceuticals Incorporated
Sector
Industry
CEO
Reshma Kewalramani
Website
Headquarters
Boston
Founded
1989
ISIN
US92532F1003
FIGI
BBG000GNZSN6
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Related stocks
VRTX Tight Triangle Breakout – Watch Closely
🧠 Chart Analysis Summary:
Pattern: A symmetrical triangle is visible, tightening toward the apex with a breakout just forming.
Current Price: $472.47 (breakout near)
Key Levels:
Support Zone: Around $468–470 (white/yellow zone)
Resistance Zone:
First Target: $477.01 (red line)
Major Target:
Not many areas confident of a continuationConsolidating, for sure. However, it doesn't seem to have the drive and momentum for continuation unless more buyers come in; this is pointing in a very bearish direction.
Replenishment mid 400s? Surely?As it happens, this is from earlier, but now that we're seeing the same signs we did previously, it suggests the same can happen.
Its either now or never as it reaches previous high testBreak the candle and move on to the 52-week test. This has been turbulent up and down, and there is no escaping the current path to its momentum unless we see a break in structure.
another flush from a promising start 450 not farThe stock swings have been trying to position themselves into an upswing trending faction. However, they have failed to materialize and have LS from making new highs, an early indication that things may need re-evaluation.
VERTEX ($VRTX) SHINES IN Q4—PAIN & CF FUEL GROWTHVERTEX ( NASDAQ:VRTX ) SHINES IN Q4—PAIN & CF FUEL GROWTH
(1/9)
Good evening, Tradingview! Vertex ( NASDAQ:VRTX ) is buzzing—Q4 revenue up 16%, new drugs hit the scene 📈🔥. $ 2.91B and a bold 2025 forecast—let’s unpack this biotech beast! 🚀
(2/9) – REVENUE RUSH
• Q4 Haul: $ 2.91B—16% jump from l
$VRTX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for NASDAQ:VRTX after a negative under reaction following its earnings release placing the stock in drift D with an expected accuracy of 85.71%.
Vertex Pharmaceuticals Pulls Back After RallyVertex Pharmaceuticals ended January with a big rally. Now, after a pullback, some traders may see an opportunity.
The first pattern on today’s chart is the price gap on January 31 after the FDA approved its Journavx painkiller. (It’s the first of its kind to treat pain in a unique way without addi
Can Pain Be Managed Without Addiction?Vertex Pharmaceuticals has achieved a monumental breakthrough in pain management, securing FDA approval for Journavx, the first new class of painkiller in over 20 years. This non-opioid drug introduces a paradigm shift, targeting pain signals directly at the source without the addictive risks associ
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where VX1 is featured.
Frequently Asked Questions
The current price of VX1 is 335.60 EUR — it has decreased by −0.64% in the past 24 hours. Watch Vertex Pharmaceuticals Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange Vertex Pharmaceuticals Incorporated stocks are traded under the ticker VX1.
VX1 stock has risen by 0.71% compared to the previous week, the month change is a 3.97% rise, over the last year Vertex Pharmaceuticals Incorporated has showed a −20.32% decrease.
We've gathered analysts' opinions on Vertex Pharmaceuticals Incorporated future price: according to them, VX1 price has a max estimate of 535.65 EUR and a min estimate of 283.28 EUR. Watch VX1 chart and read a more detailed Vertex Pharmaceuticals Incorporated stock forecast: see what analysts think of Vertex Pharmaceuticals Incorporated and suggest that you do with its stocks.
VX1 stock is 1.71% volatile and has beta coefficient of 0.55. Track Vertex Pharmaceuticals Incorporated stock price on the chart and check out the list of the most volatile stocks — is Vertex Pharmaceuticals Incorporated there?
Today Vertex Pharmaceuticals Incorporated has the market capitalization of 86.70 B, it has increased by 0.43% over the last week.
Yes, you can track Vertex Pharmaceuticals Incorporated financials in yearly and quarterly reports right on TradingView.
Vertex Pharmaceuticals Incorporated is going to release the next earnings report on Oct 29, 2025. Keep track of upcoming events with our Earnings Calendar.
VX1 earnings for the last quarter are 3.84 EUR per share, whereas the estimation was 3.63 EUR resulting in a 5.80% surprise. The estimated earnings for the next quarter are 3.93 EUR per share. See more details about Vertex Pharmaceuticals Incorporated earnings.
Vertex Pharmaceuticals Incorporated revenue for the last quarter amounts to 2.50 B EUR, despite the estimated figure of 2.47 B EUR. In the next quarter, revenue is expected to reach 2.61 B EUR.
VX1 net income for the last quarter is 876.83 M EUR, while the quarter before that showed 597.40 M EUR of net income which accounts for 46.77% change. Track more Vertex Pharmaceuticals Incorporated financial stats to get the full picture.
No, VX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 8, 2025, the company has 6.1 K employees. See our rating of the largest employees — is Vertex Pharmaceuticals Incorporated on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vertex Pharmaceuticals Incorporated EBITDA is 3.91 B EUR, and current EBITDA margin is 41.56%. See more stats in Vertex Pharmaceuticals Incorporated financial statements.
Like other stocks, VX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vertex Pharmaceuticals Incorporated stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vertex Pharmaceuticals Incorporated technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vertex Pharmaceuticals Incorporated stock shows the sell signal. See more of Vertex Pharmaceuticals Incorporated technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.